Zobrazeno 1 - 4
of 4
pro vyhledávání: '"MESH: HIV Fusion Inhibitors"'
Autor:
Lévy, Yves, Lelièvre, Jean-Daniel, Assoumou, Lambert, Aznar, Esther, Pulido, Federico, Tambussi, Giuseppe, Crespo, Manuel, Meybeck, Agnès, Molina, Jean-Michel, Delaugerre, Constance, Izopet, Jacques, Peytavin, Gilles, Cardon, Fanny, Diallo, Alpha, Lancar, Rémi, Béniguel, Lydie, Costagliola, Dominique
Publikováno v:
Annals of Internal Medicine
Annals of Internal Medicine, American College of Physicians, 2020, 172 (5), pp.297-305. ⟨10.7326/M19-2133⟩
Annals of Internal Medicine, American College of Physicians, 2020, 172 (5), pp.297-305. ⟨10.7326/M19-2133⟩
International audience; Background: Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretroviral therapy (c-ART). Objective : To assess the benefit of adding maraviroc, an antiretroviral drug with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4325::373c10ef5347e3e82082d01fcacfc7e0
https://ut3-toulouseinp.hal.science/hal-03578146
https://ut3-toulouseinp.hal.science/hal-03578146
Autor:
Recordon-Pinson, Patricia, Soulié, Cathia, Flandre, Philippe, Descamps, Diane, Lazrek, Mouna, Charpentier, Charlotte, Montes, Brigitte, Trabaud, Mary-Anne, Cottalorda, Jacqueline, Schneider, Véronique, Morand-Joubert, Laurence, Tamalet, Catherine, Desbois, Delphine, Macé, Muriel, Ferré, Virginie, Vabret, Astrid, Ruffault, Annick, Pallier, Coralie, Raymond, Stéphanie, Izopet, Jacques, Reynes, Jacques, Marcelin, Anne-Geneviève, Masquelier, Bernard, Renseigné, Non
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2010, 54 (8), pp.3335-40. ⟨10.1128/AAC.00148-10⟩
Antimicrobial Agents and Chemotherapy; Vol 54
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2010, 54 (8), pp.3335-40. ⟨10.1128/AAC.00148-10⟩
Antimicrobial Agents and Chemotherapy; Vol 54
Genotypic algorithms for prediction of HIV-1 coreceptor usage need to be evaluated in a clinical setting. We aimed at studying (i) the correlation of genotypic prediction of coreceptor use in comparison with a phenotypic assay and (ii) the relationsh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c57178d99db6ebdc6ec5ac609e7363c
https://doi.org/10.1128/aac.00148-10
https://doi.org/10.1128/aac.00148-10
Autor:
P, Recordon-Pinson, S, Raymond, P, Bellecave, A G, Marcelin, C, Soulie, D, Descamps, V, Calvez, P R, Harrigan, H, Fleury, J, Izopet, B, Masquelier, Theresa, Mo
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 2013, 57 (2), pp.930-935. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, 2013, 57 (2), pp.930-5. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (2), pp.930-5. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (2), pp.930-935. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy; Vol 57
Antimicrobial Agents and Chemotherapy, 2013, 57 (2), pp.930-935. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, 2013, 57 (2), pp.930-5. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (2), pp.930-5. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (2), pp.930-935. ⟨10.1128/AAC.02159-12⟩
Antimicrobial Agents and Chemotherapy; Vol 57
There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40ea6f53b20ce343fe2ddb8bf3f6231
https://hal.science/hal-01101119
https://hal.science/hal-01101119
Autor:
Claudio Maria Mastroianni, Raffaella Rossi, Fabio Mengoni, Miriam Lichtner, Ilaria Sauzullo, Vincenzo Vullo, Anna Paola Massetti, A. De Rosa
Publikováno v:
Clinical and Experimental Immunology
Clinical and Experimental Immunology, Wiley, 2011, 166 (2), pp.184-90. ⟨10.1111/j.1365-2249.2011.04409.x⟩
Clinical and Experimental Immunology, Wiley, 2011, 166 (2), pp.184-90. <10.1111/j.1365-2249.2011.04409.x>
Clinical and Experimental Immunology, Wiley, 2011, 166 (2), pp.184-90. ⟨10.1111/j.1365-2249.2011.04409.x⟩
Clinical and Experimental Immunology, Wiley, 2011, 166 (2), pp.184-90. <10.1111/j.1365-2249.2011.04409.x>
Summary Compounds targeting the chemokine receptor CCR5 have recently been approved for treatment of human immunodeficiency virus (HIV) infection. Given the central role of CCR5 in inflammation and recruitment of antigen-presenting cells (APC), it is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a531c21a8dad2cd1218d66d25fac96ec
http://hdl.handle.net/11573/503070
http://hdl.handle.net/11573/503070